compared the plasma dexamethasone levels after 1-mg DST in healthy obese participants and in normal-weight participants. Plasma dexamethasone, Dexamethasone levels, 1-mg dexamethasone suppression test, Obesity
Conditions
Interventions
Obese participants had a 1-mg dexamethasone administered orally at 11.00 p.m and then plasma dexamethasone level were obtained at 8.00-9.00 a.m. on the next day ,Non-obese participants had a 1-mg dexa
Experimental Drug,Experimental Drug
1 mg Dexamethasone,1 mg Dexamethasone
Sponsors
Ratchadapisek Research Funds
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: participants aged more than 18 years
Exclusion criteria
Exclusion criteria: -pregnancy, diabetes mellitus, known CS, psychiatric disease, chronic liver disease, chronic renal failure stage 3 to 5, nephrotic syndrome, malabsorption disease -Heavy alcohol drinking more than 30 gm/day -taking drugs that interfering CYP3A4 within 1 month or oral contraceptives within 6 weeks prior to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare plasma dexamethasone levels after 1-mg DST in obese participants and in normal-weight participants 12 mo LC-MS/MS | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of Sex, BMI, BSA and dexamethasone level 12 mo LC-MS/MS,proportion of participants achieving the plasma dexamethasone levels more than 3.3 nmol/L among the BMI groups 12 mo LC-MS/MS | — |
Countries
Thailand
Contacts
Public ContactPimonrat Paopongpaiboon
Chulalongkorn University
Outcome results
None listed